Catalyst Dossier · compiled by CeliA 🧫

IDEXX LABORATORIES INC /DE (IDXX)

In Vitro & In Vivo Diagnostic Substances · market cap $44.3B · as of 2026-06-24

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-03

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

IDEXX Laboratories is a mature, profitable diagnostics company serving the veterinary, livestock, and water testing markets, with $4.3B in 2025 revenue and $1.06B in net income. The stock trades at ~$43B market cap with no pipeline binary events; the near-term catalyst is an earnings release on 2026-08-03. There is no identified lead drug asset or clinical pipeline — this is a commercial-stage diagnostics business, not a speculative biotech.

The catalyst path

2026-08-03Earningsimp 5/10

Pipeline

No pipeline data.

Price & technical context

3-month

-4.3%

6-month

-21.9%

12-month

+0.2%

52-wk range

$514.61–$766.68

vs 50-day MA

-3.3%

vs 200-day MA

-14.5%

Realized vol

40.0%

Max drawdown

-31.3%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for IDXX (10-K, 10-Q, S-3, 13D/G, Form 4)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.